EEEstelle Everett

Estelle Everett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Estelle Everett has a total of 103 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Carbohydrate Counting in the Real World: Mealtime Insulin Dosing Behaviors and Smartphone App Use in Adults With Type 1 Diabetes

    by Estelle M. Everett, Erin Shaw, Bryan Escobar Barrios, Deborah Cheng, Ryan Tiu, Rebecca Lopez, Jessica Menjivar Cruz, Alejandra Rivas Deras, Danielle Polan, Lauren E. Wisk, et al.

  • Open Access

    The Emotional Burden and Behavioral Impacts of Alarms and Alerts Across the Spectrum of Diabetes Technology Use: a Cross-Sectional Study

    by Estelle Everett, Erin Shaw, Bryan Escobar Barrios, Beatrice Brumley, Kyrstin Lane, Tannaz Moin, Lauren E Wisk

    Background: Continuous glucose monitors (CGMs), sensor-augmented pumps (SAPs), and automated insulin delivery (AID) systems have substantially improved glycemic outcomes for people with type 1 diabetes (T1D). However, these technologies also generate frequent alarms and alerts that may contribute to emotional burden, alarm fatigue, and maladaptive behavioral responses. Despite increasing recognition of alarm-related distress, little is known about how alarm burden differs across contemporary diabetes technologies. Objective: This study evaluated differences in alarm frequency, emotional burden, and behavioral responses to alarms and alerts among adults using CGMs alone, SAP therapy, and AID systems. Methods: We conducted a cross-sectional survey of adults (≥18 years) with T1D receiving care within a large academic health system between August 2024 and March 2025. Eligible participants completed an online survey assessing demographics, diabetes technology use, perceptions of alarm frequency and burden, and responses to alarms and alerts. Participants were categorized as CGM-only, SAP, or AID users. Differences between groups were evaluated using χ 2 tests and ANOVA. Ordinal logistic regression models adjusted for age, gender, and diabetes duration were used to examine associations between diabetes technology type and alarm-related outcomes. Results: Among 838 respondents (mean age 46.0, SD 16.6 years; mean diabetes duration 23.0, SD 14.0 years; n=457, 55% women), AID users reported the highest alarm frequency, with 49% (252) experiencing alarms several times daily, compared with 35% (28) of SAP users and 32% (79) of CGM-only users ( P <.001). AID users also reported greater alarm disruptiveness, annoyance, and unwanted attention than CGM-only users. Overcorrection of glucose levels in response to alerts was common across all technologies: 44% (371) and 50% (419) of participants reported sometimes overcorrecting low and high glucose levels, respectively, while 32% (265) and 18% (147) reported often or always overcorrecting low and high glucose levels, respectively. After adjustment, AID users had greater odds of frequent alarms (odds ratio [OR] 1.98, 95% CI 1.48-2.65), alarm disruptiveness (OR 1.67, 95% CI 1.24-2.25), annoyance (OR 1.65, 95% CI 1.23-2.19), unwanted attention (OR 1.85, 95% CI 1.38-2.47), ignoring alarms (OR 1.86, 95% CI 1.40-2.47), and overcorrecting low glucose levels (OR 1.61, 95% CI 1.20-2.15) compared with CGM-only users. Perceived effectiveness of alarms did not differ by technology type. Conclusions: Although AID systems provide important clinical benefits, they are associated with the greatest alarm and alert burden. Alarm-driven behaviors, including ignoring alerts and overcorrecting glucose levels, represent previously underrecognized consequences of diabetes technology that may diminish user experience and potentially affect glycemic management. These findings identify opportunities to improve alert algorithms while highlighting the need for individualized patient education, clinician engagement in setting appropriate alert thresholds, and routine assessment of alarm burden to optimize both glycemic outcomes and patient-centered experiences with diabetes technology.

  • A Spanish-language educational intervention to enhance diabetes outcomes among existing continuous glucose monitor users in a federally qualified health care center.

    by Marielle Tavares, Katayoun Khoshbin, Walter Solorzano, Ligaya Scarlett, Cynthia Santana, Rebecca Lopez, Giuliana Perini Villanueva, Bryan Escobar, Kathyana Santiago Mangual, Carol Pavlish, et al.

    Latinx adults with type 2 diabetes (T2D) experience worse glycemic outcomes. Although continuous glucose monitors (CGMs) improve glycemic control, benefits often plateau after early adoption, and evidence is limited regarding post-initiation CGM-focused interventions. We conducted a single-arm pilot study among Spanish-speaking adults with T2D who were established CGM users at a federally qualified health center. Participants completed a one-time, culturally tailored CGM-focused educational session delivered in Spanish, with brief post-session follow-up support. Primary outcomes included glycemic control at 3 months. Secondary outcomes included CGM-derived metrics and patient-reported measures of glucose monitoring satisfaction, diabetes distress, and empowerment. Twenty participants (mean CGM use 16.5 months) completed the intervention. HbA1c declined but not significantly (-0.33%, p = .17). Significant improvements were observed in time in range (+11.4%, p = .03) and time in hyperglycemia (-8.7%, p < .001), without increases in hypoglycemia. Participants reported improved glucose monitoring satisfaction and reduced diabetes distress. Empowerment improved immediately post-intervention but was not sustained at 3 months. In conclusion, a culturally informed CGM-focused educational intervention was associated with clinically meaningful improvements in glycemic patterns and psychosocial outcomes among Spanish-speaking Latinx adults with long-standing CGM use, supporting its potential role in enhancing post-initiation CGM engagement and addressing disparities in diabetes.

  • Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-effectiveness

    by Giuliana Perini Villanueva, Walter M. Solorzano, Estelle Everett

    This review summarizes recent evidence on continuous glucose monitoring (CGM) in adults with type 2 diabetes mellitus (T2D), focusing on clinical effectiveness, patient-reported outcomes, disparities in use, and policy and economic considerations. Studies from 2020 to 2025 show that CGM use in T2D is associated with consistent improvements in glycosylated hemoglobin (HbA1c), time in range, and diabetes self-management across insulin and non-insulin treatment regimens. Emerging observational data suggest reductions in mortality and health care utilization, and cost-effectiveness analyses consistently demonstrate that CGM represents a high-value intervention across payer settings. Despite these benefits, CGM uptake remains variable, with persistent disparities by age, race, and ethnicity, insurance coverage, and care setting. CGM is an effective and cost-effective tool for T2D management, but inequities in access limit its impact. Future research should address implementation in safety-net and primary care settings, evaluate over-the-counter CGM, and assess long-term clinical and health system outcomes.


  • Open Access

    Impact of Medicaid Continuous Glucose Monitor Expansion on Uptake, Glycemic Outcomes, and Engagement Among Adults With Type 2 Diabetes in a Federally Qualified Health Center

    by Walter Solorzano, Ligaya Docena Scarlett, Giuliana Perini Villanueva, Kathyana Santiago Mangual, Cynthia Santana, Bryan Escobar, Angelique Rubio, Nicholas J Jackson, Marielle Tavares, Joseph Borrell, et al.

    Background: Continuous glucose monitors (CGMs) improve outcomes for adults with type 2 diabetes yet use remains low in underserved populations. California’s 2022 Medicaid coverage expansion aimed to reduce access barriers, but its impact in safety-net settings is not well understood. Methods: We conducted a retrospective cohort study of adults with type 2 diabetes receiving care at a federally qualified health center from January 2022 to June 2023. Electronic health records assessed CGM uptake and glycemic outcomes. Telephone surveys (November 2023-February 2025) evaluated patient perceptions and engagement. Time-to-event models estimated the association between CGM initiation and achieving a ≥1% hemoglobin A1c (HbA1c) reduction. Open-ended responses were analyzed thematically. Results: Among 256 adults, 126 (49%) initiated CGM use, with uptake increasing after Medicaid expansion. In the analytic sample (n = 230), CGM new users were associated with a higher but not statistically significant hazard of achieving a ≥1% HbA1c reduction (adjusted HR = 1.31; 95% CI: 0.87-1.97). Among survey respondents (n = 82), commonly cited benefits included improved glucose management and convenience, while engagement varied across behaviors. Conclusions: Medicaid coverage expansion increased CGM use in a safety-net population. High acceptability alongside variable engagement highlights the need for targeted implementation strategies to translate expanded access into equitable clinical benefit.

  • Open Access

    Knowledge of Interpreter Rights and Medication Delays in Diabetes Care

    by Miguel A. Linares, Estelle M. Everett, Jorge A. Rodriguez, Alejandra Casillas, Arleen Brown

    To examine the association between knowledge of interpreter rights and diabetes care quality and health care utilization among adults with non-English language preference (NELP) in California. We conducted a cross-sectional analysis using pooled data from the 2015–2024 California Health Interview Survey (CHIS). The study included adults with NELP, self-reported diabetes, and a usual source of care. The primary exposure was self-reported knowledge of rights to free medical interpretation. Outcomes included self-reported receipt of hemoglobin A1c, eye, and foot exams; delays or forgone medical care or prescription medications; and measures of health care utilization. Survey weighted Poisson regression models were used to estimate adjusted risk ratios (RRs) and 95% confidence intervals (CIs), controlling for sociodemographic, health, and utilization-related covariates. Among 2,379 adults with diabetes and NELP (representing an average annual weighted population of 508,871), 76.6% reported knowledge of interpreter rights. In unadjusted analyses, lack of knowledge was associated with a higher likelihood of delayed prescribed medications (RR 1.76, 95% CI 1.20–2.58). This association persisted after adjustment (aRR 1.81, 95% CI 1.24–2.63). No significant associations were observed for other diabetes care metrics or health care utilization outcomes. Associations did not differ by diabetes type. Among adults with diabetes and NELP, lack of knowledge of interpreter rights was associated with delays in obtaining prescribed medications. Interpreter rights awareness may represent a modifiable factor to improve engagement in communication-dependent aspects of diabetes care and advance language equity in health care delivery.

  • Developing and Evaluating a Natural Language Processing Algorithm to Detect Insulin Pump and Continuous Glucose Monitor Use in Electronic Health Records of Patients with Type 1 Diabetes

    by Estelle Everett, Ryan A. Tiu, Bing Zhu, Jeffrey Feng, Nicholas Jackson, Joyce Graham, Eli Ipp, Nestoras Mathioudakis, Alex A.T. Bui, Tannaz Moin

    Objective: We aimed to develop and validate natural language processing (NLP) algorithms to identify insulin pump and continuous glucose monitor (CGM) users using unstructured clinical note data from the electronic health record (EHR). Methods: We reviewed a random sample of outpatient clinical notes from endocrinologists to catalog how insulin pump and CGM use was documented. We translated these patterns into regular expressions and used them to build rule-based NLP algorithms, which we iteratively refined. We evaluated the final algorithms in a University of California Los Angeles (UCLA) holdout dataset that included the most recent note from 667 unique patients. We then externally validated the algorithms in a second health system with a different EHR and patient population. Manual chart review served as the gold standard. We assessed performance with measures including sensitivity and specificity. To contextualize algorithm performance, we evaluated the accuracy of billing codes for insulin pump and CGM use within the same UCLA holdout dataset. Results: In the UCLA holdout dataset, our insulin pump algorithm achieved a sensitivity of 0.90 and specificity of 0.89. The CGM algorithm achieved a sensitivity of 0.85 and specificity of 0.84. The combined algorithm identifying both insulin pump and CGM use showed a sensitivity of 0.76 and specificity of 0.92. In comparison, billing codes underperformed: International Classification of Diseases/Current Procedural Terminology (CPT) codes identified insulin pump use with a sensitivity of 0.09 and specificity of 1.00, whereas CPT codes identified CGM use with a sensitivity of 0.68 and specificity of 0.86. For combined device use, billing codes had a sensitivity of 0.06 and specificity of 1.00. External validation demonstrated similarly strong algorithm performance in the second health system. Conclusions: We showed that NLP can accurately identify insulin pump and CGM users from unstructured EHR notes, substantially outperforming billing code-based methods. This scalable approach can support system- and population-level evaluations of diabetes technologies.

  • Open Access

    Determining Insulin Pump Candidacy: The Disconnect Between Clinical Care Guidelines and Clinical Practice

    by Estelle Everett, Lisa Dao, Nagambika Munaganuru, Kelechi Udeze, Samantha Gutierrez, Sarah Gann, Ashley Meda, Ryan Tiu, Amanda Arevalo, Chanelz Drexler, et al.

    Objective: We evaluated provider sentiments and practices that influence recommendations for insulin pump use. Methods: We surveyed US adult endocrinologists and used descriptive statistics to assess guideline adherence and criteria for insulin pump candidacy. Providers were categorized as permissive or selective prescribers based on reliance on criteria outside of clinical guidelines. Adjusted logistic regression identified factors associated with selective prescribing. Results: In 2023, we emailed surveys to 5684 endocrinologists, and 299 (5%) responded. Criteria for insulin pump use varied across providers: carbohydrate counting (55%), a minimum number of daily glucose checks (51%), a minimum number of clinic visits (48%), continuous glucose monitor use (42%), a minimum duration after diagnosis (20%), and a specific A1c (8%). While 94% reported being aware of diabetes care guidelines, 52% almost never referenced guidelines when determining insulin pump candidacy. The majority reported relying on their own judgment about insulin pump candidacy when it conflicted with clinical guidelines. Selective prescribers were more likely to report using guidelines sometimes or more (vs not often/never), have a low proportion of diabetes in their clinical case mix, and see patients primarily with public insurance. Conclusion: Less than half of endocrinologists referenced national guidelines for pump candidacy, with many relying on nonevidence-based criteria. These findings demonstrate an important disconnect between guideline recommendations and clinical practice that may lead to underutilization of insulin pumps, which can enhance diabetes care and outcomes. Additional work is needed to better align clinical practice with current recommendations.


  • Association Between Self-Monitored Blood Glucose and Continuous Glucose Monitoring in Youth With Type 1 Diabetes and Medicaid Insurance

    by Janice Chan, Nicholas Jackson, Arianna Gonzalez Rebollar, Cynthia Santana, Giselle Perez de la Garza, Tannaz Moin, Jennifer K. Yee, Estelle Everett

    OBJECTIVE: Youth with type 1 diabetes (T1D) and Medicaid must demonstrate they have self-monitored their blood glucose level at least four times daily to receive continuous glucose monitors (CGMs). New California Medicaid policies eliminated this requirement and, thus, CGM access has increased. This study examines whether infrequent baseline self-monitored blood glucose (SMBG) checks result in suboptimal outcomes or nonadherence with CGM use. RESEARCH DESIGN AND METHODS: This retrospective study included youth with T1D and Medicaid who started CGM after January 2019, when newer models no longer needed calibration, at two large health care systems. Patients were stratified by data on baseline SMBG frequency (<4 vs. ≥4 checks daily) collected at the clinic visit prior to starting CGM. Differences between SMBG groups in CGM adherence and HbA1c over time were assessed by a mixed-effects linear regression model and fixed-effect interaction term. Patients were surveyed to explore individual impact of CGM on diabetes management. RESULTS: We followed 78 youth for 6 months. CGM adherence was similar between SMBG frequency groups at 3 months (68.7% vs. 68.4%; P = 0.97) and sustained at 6 months. HbA1c values improved in both groups at 3 months, with a larger improvement in those with SMBG <4 daily checks (1.3% vs. 0.4%), and sustained at 6 months. Patient surveys (n = 35) reported high engagement with CGM and increased insulin boluses after initiation. CONCLUSIONS: Patients using CGM demonstrated improvement in HbA1c regardless of prior SMBG. Increased engagement with CGM likely promoted increased insulin boluses. Therefore, restriction of CGM to those with SMBG ≥4 daily checks is an unnecessary barrier, excluding those who could potentially benefit the most.


  • Open Access

    Impact of a Nurse Practitioner–Led Diabetes Program on Barriers to CGM Use in a Federally Qualified Health Center After Medicaid Expansion

    by Ligaya Docena Scarlett, Walter Solorzano, Katayoun Khoshbin, Giuliana Perini Villanueva, Kathyana Santiago Mangual, Marielle Tavares, Cynthia Santana, Bryan Escobar, Joseph Borrell, Beatrice Brumley, et al.

    Objective: Continuous glucose monitors (CGMs) enhance diabetes management, but disparities exist, particularly among underserved populations in federally qualified health centers (FQHCs). In 2022, a California Medicaid policy change expanded CGM coverage, providing an opportunity to better evaluate barriers to CGM use within primary care in an FQHC. Methods: We used 2022–2023 electronic health record (EHR) data to identify adults with diabetes managed on insulin within a nurse practitioner–led diabetes program in primary care. Patients were categorized as current, former, or never CGM users. We used summary statistics, chi‐squared, and Bartlett′s tests to assess unadjusted group differences and multivariate logistic regression to identify factors associated with former or never use. All patients were invited to complete a survey on CGM facilitators and barriers. Results: Among 275 eligible patients, 109 (40%) were current CGM users, 31 (11%) former users, and 135 (49%) never users. Discussions on CGM occurred in 45% of never users, who were more likely to have non‐Medicaid insurance, fewer than five clinic visits (OR 3.69, 95% CI: 1.94–6.99), and a lower baseline A1C (OR 0.67, 95% CI: 0.52–0.86). No demographic or clinical factors were associated with former CGM use. Among survey respondents ( n = 124), the desire to reduce finger‐pricks motivated CGM use, while device burden and inconvenience contributed to discontinuation or refusal. Conclusions: Medicaid policy expansion reduced major structural barriers to CGM use, yet some patient‐related barriers persisted. Team‐based care models integrating health educators and advanced practice providers can successfully support CGM access and sustained use in underserved populations.